Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Umeclidinium/Vilanterol in COPD
NCT01313650Phase 3Completed
- Sponsor
- GSK
- Start
- Mar 2011
- Primary completion
- Apr 2012
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of umeclidinium and vilanterol in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by GSK. Primary endpoint: Trough Forced Expiratory Volume in One Second at Day 169. Started Mar 2011; status: completed.
02
Drugs
umeclidiniumvilanterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01313650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01313650.